The PI3K pathway is frequently hyperactivated in primary T-cell acute lymphoblastic leukemia (T-ALL) cells. Activation of the PI3K pathway has been suggested as one mechanism of glucocorticoid resistance in T-ALL, and patients harboring mutations in the PI3K negative regulator PTEN may be at increased risk of induction failure and relapse. By gene expression microarray analysis of T-ALL cells treated with the PI3K inhibitor AS605240, we identified Myc as a prominent downstream target of the PI3K pathway. A significant association was found between the AS605240 gene expression signature and that of glucocorticoid resistance and relapse in T-ALL. AS605240 showed anti-leukemic activity and strong synergism with glucocorticoids both in vitro and in a NOD/SCID xenograft model of T-ALL. In contrast, PI3K inhibition showed antagonism with methotrexate and daunorubicin, drugs that preferentially target dividing cells. This antagonistic interaction, however, could be circumvented by the use of correct drug scheduling schemes. Our data indicate the potential benefits and difficulties for the incorporation of PI3K inhibitors in T-ALL therapy.
INTRODUCTION
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic cancer [1] . The prognosis of children with T-ALL has improved with modern treatment protocols, based on the use of aggressive multiagent therapies [2] . However, T-ALL patients displaying chemotherapy resistance show very poor survival. Accumulating evidence indicates that the PI3K pathway is linked to resistance to therapy in several types of cancer [3] .
Class I PI3Ks are a family of lipid kinases predominantly activated by protein tyrosine kinases in response to cell surface receptors. PI3K phosphorylates phosphatidylinositol 4, 5-bisphosphate (PIP 2 ) generating phosphatidylinositol 3, 4, 5-trisphosphate (PIP 3 ). PIP 3 serves as an anchor for pleckstrin homology (PH) domain-containing proteins, which initiate the assembly of signaling complexes that results in the activation of a plethora of downstream effector molecules, including protein kinase B (Akt) [4] and the mammalian target of rapamycin complex 1 (mTORC1) [5] . The PI3K pathway is central to the control of cell survival, energy metabolism, cellular motility and cell cycle progression [6] [7] .
Constitutive activation of the PI3K pathway in hematological malignancies has been shown to support tumor cell proliferation, viability and drug resistance in vitro [8] [9] [10] . Moreover, PI3K signaling pathway is frequently hyperactivated in primary T-ALL cells, for instance due to microenvironmental stimulation, interleukin-7 receptor (IL7R) oncogenic mutations or phosphatase and tensin homolog (PTEN) inactivation [11] [12] [13] [14] [15] . Activation of the PI3K effector mTOR in T-ALL has been suggested to represent one mechanism of resistance to glucocorticoids, a common feature of relapse [16] [17] . Moreover, synergistic effects of inhibitors of the PI3K-downstream mTOR pathway in T-ALL cell lines have been described [18] [19] . We and others have shown that T-ALL patients harboring PTEN mutations may be at increased risk of induction failure and relapse [13, 20] . Importantly, PTEN aberrations were associated with poor outcome and relapse in T-ALL [20] [21] [22] , suggesting that the level of PI3K activation may influence resistance to treatment.
In this study, T-ALL cells were treated with a PI3K inhibitor to identify a transcriptional PI3K activity signature. PI3K inhibition downregulated genes associated with cellular growth and targets of Myc. Moreover, the comparison of the PI3K signature with gene expression data of primary T-ALL samples indicates that higher PI3K activity is associated with glucocorticoid resistance and worse clinical outcome. We opted to use the PI3K inhibitor AS605240 in light of its favorable pharmacological and biochemical characteristics [23] [24] . This allowed us to test the long term inhibition effects of PI3K in a NOD/SCID xenograft model of T-ALL. Functional assays demonstrated that PI3K inhibition sensitizes T-ALL cells to glucocorticoids, but antagonizes methotrexate (MTX) and daunorubicin (DNR), unless correct drug scheduling is used.
RESULTS

PI3K activity is associated with increased chemotherapy resistance and poor prognosis in T-ALL
Most cell lines are maintained in culture for years and accumulate several genetic lesions not characteristic of primary disease [25] . On the other hand, ALL primary cells do not divide in vitro [26] , which may affect their response to small molecules [27] . Hence, we decided to obtain transcriptional signatures of PI3K activity from both cell lines and primary cells, which would provide complementary aspects of gene expression modulation by PI3K. To do so, seven T-ALL cell lines [GSE50998] and 15 diagnostic T-ALL patient samples [GSE51000] were treated with the PI3K inhibitor AS605240 or vehicle for 6 h, and subjected to global gene expression analysis using whole-transcript Affymetrix expression arrays. Principal Component Analysis (PCA) showed that most samples responded similarly to PI3K inhibition, irrespectively of PTEN and NOTCH1 mutational status (Supplementary Figure 1) . Using paired Limma analysis, we obtained 211 genes downregulated and 78 genes upregulated in T-ALL primary cells (adjusted p-value < 0.05, FC > 1.5; Supplementary Table 1) and 174 genes downregulated and 395 genes upregulated in T-ALL cell lines (adjusted p-value < 0.05, FC > 1.5; Supplementary Table 2) in response to AS605240 treatment. As expected, Connectivity Map analysis showed that the signature resulting from PI3K inhibition in T-ALL cell lines correlated with signatures of classical PI3K inhibitors (wortmannin and LY-294002), and rapamycin (sirolimus; Supplementary Figure 2) . Rapamycin is an inhibitor of mTORC1, a complex downstream of PI3K signaling [5] . Although other interpretations may be possible, genes downregulated by AS605240 were here considered to be under positive transcriptional control of PI3K, whereas those upregulated by AS605240 were considered under negative control of PI3K.
GSEA analysis showed that AS605240 treatment downregulated several gene sets related to cellular growth in both T-ALL cell lines and primary cells, including energy metabolism (glucose transport and metabolism, oxidative phosphorylation, pyruvate metabolism, and TCA cycle), transcription (nucleotide metabolism, RNA polymerase III transcription, tRNA and miRNA biosynthesis) and biosynthesis of a plethora of compounds and cellular structures (biosynthesis of purines, pyrimidines, amino acids, glucose, fatty acids and steroids, and biogenesis of lysosome vesicles and mitochondria). Among the top tier of gene sets transcriptionally downregulated by AS605240 in both cell lines and primary cells, four different gene sets represented targets of Myc (Figure 1a-1d; Supplementary Figure 3a -b) [28] [29] [30] . A fifth gene set representing a Myc oncogenic signature [31] was downregulated by AS605240 in cell lines (Supplementary Figure 3b) .
The transcription factor Myc is a master regulator of cell growth and multiple biosynthetic and metabolic pathways [32] , and its expression correlates with leukemia initiating activity in T-ALL [33] . Myc inhibition by AS605240 appeared to be Notch1-independent, since Notch1 direct targets [34] were not transcriptionally modulated (Figure 1e-1f) . On the other hand, a broader gene set of Notch1-responsive genes, which includes several Myc targets [35] , was significantly downregulated in cell lines treated with AS605240 (Supplementary Figure 3c) . Although MYC mRNA levels were not significantly altered after 6 h of AS605240 treatment (data not shown), western blotting analysis evidenced decreased Myc protein levels in Jurkat and Molt-4 cells after PI3K inhibition (Figure 1g ). Quantitative PCR confirmed downregulation of Myc targets ALOX5AP, BCAT1, PRDX4 and LDHA in primary cells treated with AS605240 (Supplementary Figure 3d) . BCAT1 was found to induce cell proliferation, migration and invasion in nasopharyngeal carcinoma [36] . LDHA and PRDX4 were described as overexpressed in high-risk neuroblastomas independently of other markers [37] [38] .
Ingenuity Pathway Analysis showed that the top biological functions downregulated by AS605240 in both cell lines and primary cells were related to cholesterol biosynthesis (Supplementary Figure 4) . Glucocorticoid resistance in T-ALL has been associated to the upregulation of genes linked to cellular respiration, biosynthetic and metabolic pathways, proliferation and Myc. Notably, genes responsible for cholesterol biosynthesis were found highly upregulated in prednisolone resistant T-ALL [39] , and ALL cells were shown to be particularly dependent on endogenously synthesized cholesterol, which is essential for the synthesis of cellular membranes of highly proliferative cells [40] . Because PI3K inhibition targeted genes involved in Myc signaling, cellular growth, and cholesterol biosynthesis, we hypothesized that the AS605240-derived signature would be correlated with gene expression patterns of glucocorticoid resistance in T-ALL. Indeed, GSEA analysis showed that genes associated with prednisolone resistance [39] were downregulated due to PI3K inhibition (Figure 1h ), whereas those associated with prednisolone sensitivity [39] were upregulated (Figure 1i) . The PI3K activity signatures were then compared against expression microarray data of 43 primary T-ALL samples obtained at diagnosis from patients treated under [39] were downregulated in AS605240-treated cell lines and genes discriminative for prednisolone sensitivity [39] were upregulated in AS605240-treated ones.
the GBTLI ALL-99 [41] and GBTLI-2009 protocols at Centro Infantil Boldrini [GSE50999] (for clinical and biological data, refer to Supplementary Table 3 ). GSEA analysis showed that patients that underwent relapse had higher expression of genes under positive control of PI3K (downregulated by AS605240) and lower expression values of genes under negative control of the pathway (upregulated by AS605240; Figure 2 ). Altogether, our gene expression data suggest that higher PI3K activity may be associated with increased glucocorticoids resistance and poor prognosis, which is in accordance with previous data showing that PTEN mutated patients may be at increased risk of early treatment failure and relapse [13, 20] .
The PI3K inhibitor AS605240 shows anti-leukemic activity and prevents leukemic progression in T-ALL engrafted NOD/SCID mice
Next, we sought to characterize the effects of AS605240 against T-ALL cells, with the goal of preclinically assessing the potential benefits of PI3K inhibition in T-ALL. AS605240 inhibited p-Akt (Figure 3a 
AS605240 synergizes with glucocorticoids both in vitro and in a mouse xenograft model of T-ALL
To further evaluate the clinical potential of PI3K inhibition for T-ALL treatment, we measured the cytotoxic effect of AS605240 in combination with commonly used chemotherapeutic drugs (Table 1) . We observed a synergistic interaction between AS605240 and a glucocorticoid (prednisolone) in 5 out of 6 cell lines tested ( Figure 4a ). Notably, cell lines intrinsically more resistant to prednisolone (CCRF-CEM, HPB-ALL and Molt-4) showed weaker synergism between AS605240 and prednisolone, characterized by higher Combination Index [42] [43] . In agreement with that, these cell lines were more resistant to prednisolone than the remaining cell lines analyzed. Jurkat cells showed the highest calculated IC 50 value of prednisolone. For this cell line, we were unable to measure the CI between prednisolone and AS605240.
Accordingly, NOD/SCID mice engrafted with primary T-ALL cells derived from two patient samples showed enhanced survival when treated with a combination of AS605240 (30 mg/kg once a day) and another glucocorticoid (dexamethasone), in comparison to treatment with either drug alone (Figure 4c ). Noteworthy, no difference was observed in weight loss of T-ALL transplanted NOD/SCID mice treated with AS605240 versus dexamethasone (Supplementary Figure 7) . In conclusion, our data strongly suggest that PI3K inhibition potentiates the activity of glucocorticoids against T-ALL cells both in vitro and in vivo.
PI3K inhibition requires scheduling when combined with drugs that target dividing cells
AS605240 showed an antagonistic interaction in vitro with both MTX (Table 1; Figure 5a ) and DNR (Table 1 ) in all cell lines tested. MTX is an antimetabolite that allosterically inhibits dihydrofolate reductase (DHFR), which participates in the synthesis of tetrahydrofolate, an essential molecule for the biosynthesis of purines, thymidylate and several amino acids [44] . MTX acts specifically during DNA and RNA synthesis, and thus it is cytotoxic during the S-phase of the cell cycle. AS605240 treatment completely abrogated MTX-induced S-phase arrest in vitro (Figure 5b) . Part of this antagonistic interaction may result from AS605240-induced G 0 / G 1 cell cycle arrest, which decreases the number of S-phase MTX-susceptible cells (Table 2, Figure 5b ). BrdU incorporation assays also showed decreased rate of nucleotide incorporation during S-phase in Jurkat, Molt-4 and P12-ICHIKAWA cells after 24 h treatment with AS605240 (Table 2, Figure 5c ). The lower rate of DNA duplication in AS605240-treated cells may induce increased tolerance to lower nucleotide availability under MTX treatment [45] . Altogether, these results indicate that both AS605240-induced cell cycle arrest at G 0 /G 1 and the lower rate of DNA replication may contribute to the antagonistic interaction between AS605240 and MTX.
Based on these evidences, we explored alternative administration schedules to find possible therapeutic windows for AS605240 use in the context of modern ALL treatment protocols, which include MTX and other anticancer drugs that target dividing cells. When AS605240 Figure 5d ). Noteworthy, when using this schedule, the most synergistic interactions were observed for the cell lines (HPB-ALL, CI = 1.0; P12-ICHIKAWA, CI = 0.76; ALL-SIL, CI = 0.96) found to be resistant to MTX in a 48 h assay (Figure 5e ). Overall, our data indicate that scheduling is of major importance when considering the introduction of PI3K inhibitors in T-ALL treatment schemes with chemotherapeutic drugs that require cell division.
DISCUSSION
Aberrant activation of PI3K signaling pathways has been implicated in many types of cancer [46] . PTEN mutations and elevated Akt activity were found to be associated with poor prognosis in solid tumors [47] [48] and T-ALL [13, 20] . In this study, we show data indicative of higher PI3K pathway activity in patients who underwent relapse.
Given that PI3Kγ is predominantly expressed in the hematopoietic system [49] , the use of a PI3Kγ specific inhibitor could offer an innovative rationale-based therapeutic strategy for T-ALL. AS605240 was previously described as an isoform-selective ATP-competitive inhibitor of PI3Kγ with 30-fold selectivity over PI3K δ and β, and 7.5-fold selectivity over PI3Kα [23] . However, we found that AS605240 did not have cytotoxic effects against T-ALL cells at concentrations expected to inhibit solely PI3Kγ (0.1-0.2 μM) [23] , being cytotoxic only at concentrations high enough to inhibit more than 70% of p-Akt accumulation (Figure 3b) , presumably disrupting the activity of several PI3K isoforms. All PI3K p110 subunits are highly expressed in primary T-ALL cells (Supplementary Figure 8) [50] and evidence points to roles of PI3Kα, γ and δ in T-ALL leukemogenesis [13, 50] , suggesting that multiple isoforms of PI3K might play a role in T-ALL.
Although the concentrations of AS605240 needed to inhibit the PI3K pathway and induce cell death in vitro were in the micromolar range, the drug was more selective to leukemic cells than to normal thymocytes. More importantly, the PI3K inhibitor prevented primary T-ALL progression in vivo and may be given to mice for months without inducing generalized toxicity [23] [24] . Although this indicates the feasibility of AS605240 use to treat T-ALL patients, we observed that mice had mobility difficulties and remained immobile for several minutes after AS605240 administration (Supplementary Video). This raises the possibility of undesirable neurological side effects not previously reported.
This is the first time that gene products downstream of PI3K have been identified in T-ALL. Interestingly, we observed a prominent effect of PI3K inhibition on the expression of Myc target genes. The PI3K/Akt/ mTORC1 pathway is known to positively regulate Myc protein abundance. Previous work in T-ALL demonstrated that Akt phosphorylates and deactivates Gsk3-beta, preventing phosphorylation of Myc and its degradation through the ubiquitin/proteasome pathway [51] . mTORC1 phosphorylates S6K1 which in turn enhances translation of Myc mRNA by modulating the phosphorylation of eukaryotic initiation factor eIF4B [52] . At the transcriptional level, in T-ALL, Myc is under control of Notch1 [53] . Our microarray data showed no regulation of Notch1 direct targets in response to AS605240, suggesting that the effect of this drug on Myc targets most likely occurred by posttranscriptional inhibition of Myc. Accordingly, Myc protein levels were downregulated in response to AS605240.
Glucocorticoids play a role of great importance in contemporary ALL treatment protocols. Early response to glucocorticoids is an informative prognostic factor in childhood ALL [54] and glucocorticoid resistance is a well-documented feature of relapse [17, 55] . Glucocorticoid resistance was previously associated with a proliferative phenotype involving upregulation of glycolysis, cholesterol biosynthesis, and activation of PI3K/Akt/mTOR and Myc signaling pathways [39, 56] . Indeed, fast growing T-ALL cell lines are more resistant to both prednisolone and dexamethasone [39] . Previous studies observed a synergistic interaction between rapamycin and dexamethasone in T-ALL [16, 57] . Moreover, the PI3K inhibitor LY294002 sensitized MLL-rearranged ALL cells to prednisolone in vitro [58] .
In the present study, we showed that PI3K inhibition promotes downregulation of metabolic and biosynthesis pathways towards a gene expression profile more typical of glucocorticoid sensitive ALL cases. The PI3K inhibitor AS605240 synergized with glucocorticoids in vitro and the combined use of AS605240 and dexamethasone enhanced survival of mice engrafted with T-ALL. We observed no difference between PTEN mutated and wild-type transplanted leukemias with respect to AS605240 effect, which raises the question if T-ALL patients may benefit from PI3K inhibition irrespectively of PTEN mutational status. Notably, we observed that T-ALL cell lines intrinsically more resistant to prednisolone (CCRF-CEM, HPB-ALL and Molt-4) showed weaker synergism between AS605240 and prednisolone (Figure 4a-4b ). This suggests that the PI3K pathway is not the only pathway underlying glucocorticoid resistance, corroborating previous findings [59] . Recent clinical and preclinical studies have shown that RAS mutations limit the effectiveness of PI3K inhibitors [60] [61] . AS605240 showed an antagonistic interaction with MTX and DNR when both drugs were administered simultaneously to cell cultures. MTX kills growing tumor cells by limiting their supply of dTTP and purine nucleotides, which leads to DNA repair defects, DNA strand breaks and apoptosis. MTX-induced DNA strand break accumulation is minimal in growth-arrested tumor cells [45] . The anthracycline DNR increases the levels of topoisomerase II:DNA covalently bound complexes, generating DNA double strand breaks and inducing apoptosis. Anthracyclines appear to be particularly toxic during S-phase, when replication forks and transcription complexes are both present [62] . Our results showed that PI3K inhibition in leukemia cell lines not only induces cell cycle arrest at G 0 /G 1 , but also decreases DNA synthesis rate during cell division. This cytostatic effect is probably responsible for the tolerance exhibited by AS605240-treated cells to MTX and DNR. Our data also showed that the antagonistic interaction with MTX and DNR could be successfully circumvented by means of proper drug scheduling in more than half of the cell lines studied in vitro ( Figure 5 ).
Recent evidence shows that genes most significantly correlated with ALL resistance to prednisolone are inversely correlated with MTX resistance, and that the transcriptional networks underlying resistance to one drug may actually sensitize cells to the other. Translation was suggested as one critical pathway determining the balance between glucocorticoid and MTX sensitivity in T-ALL [63] . We now provide evidence that this disparate prednisolone/MTX transcriptional profile may be under PI3K pathway control.
In summary, our gene expression analysis indicated that PI3K activity is associated with chemotherapy resistance in T-ALL. Accordingly, PI3K inhibition sensitized T-ALL cells to glucocorticoids both in vitro and in vivo. Furthermore, our data indicate that correct scheduling will be of upmost importance when combining PI3K inhibitors with drugs targeting dividing cells, which are mainstream in current protocols against T-ALL. Synthesis of AS605240. The water-soluble potassium salt of AS605240 was synthesized according to patent WO 2004007491. Identity and purity were confirmed by mass spectrometry and nuclear magnetic resonance.
METHODS
Primary T-ALL cells. Bone marrow mononuclear cells were obtained from patients with newly diagnosed T-ALL accrued from 2000 to 2013 at Centro Infantil Boldrini, Campinas, Brazil. Treatment was performed according to the Brazilian GBTLI ALL-99 [41] and GBTLI ALL-2009 protocols. NOTCH1, PTEN and IL7R were sequenced as described elsewhere [12, 20, 64] .
Cell lines culture and survival assays. Cell lines were cultured in RPMI-1640 medium, 10% fetal bovine serum (FBS), and penicillin/streptomycin at 37°C and 5% CO 2 . Medium was changed 12-24 h before all experiments. To measure IC 50 values, cells (2-6 × 10 4 ) were incubated for 96 h with increasing concentrations of AS605240, prednisolone, L-asparaginase, MTX or DNR. To measure Combination Index (CI) values between AS605240 and the other drugs, 2-fold ratios of the calculated IC 50 values (0.25x, 0.5x, 1x, 2x or 4x) of each drug were used either in combination or as single drugs. Cells were treated for a total of 96 h. When drug scheduling was applied, one of the drugs was added 48 h after the start of the experiment. Cell viability was measured by the MTT assay. IC 50 and CI values were calculated with the GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) and Calcusyn (Biosoft, Cambridge, UK) [65] [67] , only probesets identical in HG-U133A and HG-U133 Plus 2.0 arrays were used. Gene sets were considered significantly regulated when p < 0.05 and FDR < 0.25. Ingenuity Pathways Analysis (Ingenuity Systems, Redwood City, CA, USA) was performed with the Gene Symbols of AS605240 responsive genes. Principal Component Analysis was performed with the MultiExperiment Viewer (http://www.tm4.org/mev.html).
Gene expression of diagnostic T-ALL. Total RNA was extracted from T-ALL lysates preserved in guanidine isothiocyanate solution using the Illustra RNAspin Mini RNA Isolation Kit (GE Healthcare). RNA samples were processed with the WT Expression Kit (Ambion, Austin, TX, USA) and GeneChip WT Terminal Labeling and Controls Kit (Affymetrix), and hybridized on Human Gene 1.0 ST Arrays. Expression values were obtained with the iterPLIER+16 algorithm and expressed in a log2 scale. GSEA analysis was performed with 1000 gene set permutations. All array files used in this study are publicly available through the Gene Expression Omnibus (GEO) [68] .
Cell signaling assays. PIP 3 quantification of Jurkat cells (3 × 10 7 ) treated for 8 h with AS605240 IC 50 value or vehicle was performed in duplicates using the K-2500 PIP 3 In vivo experiments. Primary T-ALL cells were thawed, washed with PBS and 1 × 10 7 cells were injected in NOD/SCID (NOD.CB17-Prkdc scid /J) mice (The Jackson Laboratory, Bar Harbor, ME, USA) via the tail vein. After 10-12 weeks, successfully engrafted mice were sacrificed, T-ALL cells were collected from spleen and liver and 1 × 10 7 cells were immediately injected in higher number of non-irradiated mice for the following experiments. For disease progression experiments, mice received 20 mg/Kg of AS605240 (n = 5) or vehicle (n = 12), intraperitoneally twice a day, 5 days a week, starting on the eleventh day after injection of leukemia cells. Number of human CD45+ cells in the peripheral blood after red blood cells lysis was regularly measured by flow cytometry and exponential growth curves were compared with the F test of the best-fit K values. For survival analysis experiments, mice were randomly distributed into the different treatment groups (5 animals per group) when human CD45+ reached ≥ 0.5% of peripheral blood cells in half of the animals. Mice were treated with 30 mg/Kg of AS605240 and/or 5 mg/Kg of dexamethasone, intraperitoneally once a day, 5 days a week, for 35 days. Kaplan-Meier survival curves were compared using the log-rank test with the GraphPad Prism 5 software.
